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Autoantibodies against deoxyribonucleic acid (DNA) 
and ribonucleic acid (RNA) proteins are commonly de-
tected in patients with lupus erythematosus (LE). Anti-
bodies against native DNA are frequently detected in a 
subset of LE patients with a high prevalence of renal 
disease. Single-stranded DNA antibodies are also com-
monly detected in patients with systemic lupus erythem-
atosus (SLE) but recent evidence indicates that approx-
imately 25% of patients with benign, cutaneous (discoid) 
lupus also possess single-stranded DNA lgM autoanti-
bodies. 
LE patients also frequently possess antibodies directed 
against a variety of ribonuclear proteins (RNP). These 
RNA protein autoantibodies are generally divided into 
two groups. One group is termed snRNPs (small nuclear 
ribonuclear protein); the other is termed scRNPs (small 
cytoplasmic ribonuclear protein). Anti-RNA protein 
autoantibodies occur as frequently in patients with SLE 
as do native DNA antibodies. Furthermore, in contra-
distinction to nDNA antibodies, lupus patients generally 
make large quantities (detected by gel precipitin tech-
niques) of anti-RNP antibodies. The anti-RNP antibod-
ies are directed against proteins that bind with specific 
RNA nucleotides. The best evidence at present indicates 
that these RNA proteins containing the specific RNA 
nucleotides are involved in RNA processing and post-
translational activities such as protein synthesis. Fur-
thermore, these SLE autoantibodies are now being em-
ployed, together with other autoantibody systems de-
tected in other connective tissue diseases, to define the 
biological role of the respective RNA proteins. 
The study of autoantibodies against nucleoproteins has re-
ceived a great deal of renewed interest during the past 5 years. 
These autoantibodies are of great importa nce to the dermatol-
ogist and rheumatologist studying their association with , and 
possible pathologic role in, systemic lupus erythematosus (SLE) 
as well as other connective tissue diseases. The frequency of 
occurrence of these autoantibodies in lupus erythematosus (LE) 
Supported in part by U.S. Public Health Service grants AM 25650 
and AM 07324 from the National lnstitl{Jtes of Health, and a gift from 
t he Estee Lauder Corporation. 
Reprin t requests to: Thomas T. Provost, M.D., The Johns Hopkins 
University, School of Medicine, 600 N. Wolfe Street, Baltimore, Mary-
land 21205 . 
Abbreviations: 
BMZ: basement membra ne zone 
CIC: circulating immune complexes 
LE: lupus erythematosus 
MCTD: mixed connective tissue disease 
nDNA: antibodies against double-stra nded DNA 
RNP: ribonuclear protein(s) 
SCLE: subacute cutaneous lupus erythematosus 
scRNPs: small cytoplasmic ribonuclear proteins 
SLE: systemic lupus erythematosus 
snRNPs: sma ll nuclear ribonuclear proteins 
SS: Sjogren's syndrome 
ssDNA: denatured DNA 
Z-ONA: a nt ibodies directed against the left-handed helix variant 
of nONA 
is depicted in Table I ([1-3]; H Mogavero, D Tuffanelli , J 
Epstein, unpublished observations) . These autoantibodies are 
also now employed as probes in attempts to decipher the 
biologic role of a relatively newly described set of small molec-
ular weight ribonuclear proteins (RNP) found predominant ly 
within the nucleus and to a lesser extent, the cytoplasm of 
eukaryotic cells [ 4,5]. Finally, some of these autoantibodies are 
of great interest to immunogeneticists and immunologists 
studying the regulation of autoantibody synthesis since there 
is evidence to indicate that some of these autoantibodies are 
under genetic control by genes present in or near the HLA-DR 
loci on the major histocompatibility complex located on the 
short arm of chromosome 6 (3,6,7]. 
"LE CELL" 
From a historical viewpoint, investigations of nucleoprotein 
autoantibodies in SLE began with t he work of Haserick et a! 
and Hargraves eta! [8,9]. These investigators described the LE 
cell. The LE cell is a leukocyte which has ingested large, 
amorphous nuclear material (DNA-histone complex). The LE 
cell is produced by the DNA-histone autoantibody (LE factor) 
binding the histone nucleoprotein complex followed by the 
activation of complement. The leukocyte then, via complement 
and Fe 'Y receptors, binds and phagocytizes t he nucleoprotein 
antibody complement complex. 
ANTINUCLEAR ANTIBODIES 
Subsequent to the demonstration of the role of antinuclear 
antibodies in the formation of the LE cell, immunofluorescent 
techniques were developed which have provided a reliable tech-
nique for the determination of antibodies against nuclear con-
stituents. This technique, the fluorescent antinuclear antibody 
test (FANA), has become the most commo~ly employed screen-
ing test for the diagnosis of SLE. Approximately 90 % of SLE 
patients, using heterologous tissue i.e. , mouse liver, rat kidney, 
etc., as antinuclear antibody substrates, demonstrate signifi-
cant antinuclear antibody titers (i.e. , ~30). However, with the 
introduction of normal and malignant human cell lines as 
antinuclear antibody substrates (e.g. , KB, hep- 2, wil-2 cells) , 
the sensitivity for the detection of antinuclear ant ibodies in-
creased (10]. However, in our experience there are still some 
predominantly cutaneous lupus patients with systemic features 
who fail to give significant antinuclear antibody t iters even 
with these newer cell culture lines. We have found, these 
patients frequently possess denatured DNA (ssDNA) and/or 
Ro ant ibodies (see below) [ll]. 
In the past, specific antinuclear antibody patterns were 
judged to be significant. With the realization , however, t hat 
lupus patients make antibodies against a variety of cell con-
stituents, the specific fluorescent antibody patterns appear now 
to be of limited value. One pattern, however, if detected, should 
provoke additional studies. The peripheral or shaggy pattern 
which denotes the presence of anti-nDNA antibodies should be 
confirmed with a specific anti-nDNA assay (see below) . 
Since the late 1940's and early 1950's, the study of these 
autoantibodies has dramatically progressed. At our present 
state of evolving knowledge, 3 types of autoantibodies appear 
to be of primary importance in SLE. These are DNA, RNA, 
and histone autoantibodies. 
133s 
134s PROVOST, HERRERA-ESPARZA, AND DIAZ Vol. 85, No. 1 Supplement 
TABLE 1." Frequency of various autoantibodies 
Disease ssDNA nONA Sm nRNP Ro (SS-A) La (SS-B) Histones 
Benign cutaneous "discoid" 25%" 0 0 10% 24% 
25% 
0 
3% 
10% 
0 
SLE -90% 45% 20% 38% 33% 
90%b Drug induced lupus' 10% 0 0 0 
"Table compiled from published and unpublished data from ou r laboratory and from {2}. 
b -y M isotope. 
,. Hyd ralazine and procainamide. 
DNA ANTIBODIES 
DNA antibodies a re commonly found in SLE patients. An-
t ibodies against ssDNA, as determined by a Farr assay, have 
been reported in as many as 90% of SLE patients [3]. nDNA 
antibodies (antibodies against double-stranded DNA) have 
been reported in 40- 60% of SLE patients [1 ,2]. These nDNA 
antibodies, unlike ssDNA antibodies, are highly spec ific for 
SLE whereas, ssDNA antibodies a re also found in other con-
nective tissue diseases such as rheumatoid arthritis. Recently, 
antibod ies aga inst Z-DNA (antibodies directed against the left-
handed helix variant of nDNA) have al so been described in 
SLE patients [12]. 
There a re 4 epitopes to which DNA antibodies are commonly 
directed a lthough heterogeneity of DNA antigenic determi -
nants are frequently noted. The 4 common DNA ep itopes are: 
(1) Confirmational antigen ic determinants involving the dou-
ble-stranded helices of nDNA. These antibodies a re uncommon 
but are spec ific for SLE. (2) Antige nic determinants involving 
the phosphodieste r backbone of nDNA. Antibodies against 
these determinants cross react with ssDNA. These epitopes are 
composed of double-stranded DNA polynucleotides and syn-
thetic double-stranded polynucleotides (e.g., poly [ dA-dT]· poly 
[dA-dT] and poly dG ·poly [dC]) are capable of binding to these 
antibodies but synthetic double-stranded RNA polynucleotides 
(e.g., poly [A] ·poly [U] and poly [J] ·poly [C]) do not. (3) 
Antigenic determinants involving purine and pyrimidine bases. 
Antibodies agai nst these determinants are specific for ssDNA 
and don 't cross react with nDNA. (4) Antigenic determinants 
involving Z-DNA. Antibodies reactive against Z-DNA are of 2 
types . One type reacts with the purine and pyrimidine bases 
and, t herefore, t hese antibodies cross react with ssDNA; the 
other antibody shows spec ificity for t he Z-DNA phosphodiester 
backbone. These latte r ant ibod ies are uncommon but are spe-
cific for SLE. 
nDNA ANTIBODIES 
nDNA antibodies are highly spec ific for SLE and are com-
monly found in SLE patients with significant renal disease and 
hypocomplementemia Table ll [1 3,14] . There is ev idence that 
anti -nDNA antibodies in the form of DNA anti-DNA immune 
complexes are involved in the pathogenes is of the SLE glomer-
ulonephritis. Immunofluorescent studies have detected the 
presence of DNA in the immune deposits in affected glomeru li 
and ac id elution studies of the rena l cortices of patients dying 
with glomerulonephriti s have detected an enhanced concentra-
t ion of anti-nDNA antibodies compared to serum [14] . 
Although circulati ng immune complexes (CIC), composed of 
DNA and anti -DNA and other circulating antigen antibody 
complexes, have been viewed as the major pathologic mecha-
nism for the induction of glomerulonephritis and vasculitis in 
SLE, several new findings suggest caution in ascribing CJC to 
the pathogenesis of all the glomeru lonephritic and vasculitic 
lesions seen in SLE. For example, our preliminary data em -
ploying solid phase anti-C3 and C1q-b inding immune complex 
assays indicate no apparent co rrelation between t he quantity 
of CIC, serologic subsets of lupus, and clinical features of 
immune complex mediated di sease i.e., glomerulonephritis and 
vasculitis (R Hamilton, E Alexander, TT Provost, unpublished 
observations). Al so, recent ev idence indicates that SLE pa-
TABLE II. Features a.,sociated with nDNA antibodies 
1. i Prevalence of renal disease 
2. Hypocomplementemia 
3. Positvie lupus band test 
tients are capable of producing complement-fixing antibodies 
which bind cell surface antigens on vascular endothelium cells. 
Thus, it is conceivable that in at least some SLE patients, a 
Gell and Coombs type II reaction, may also be capable of 
inducing a significant vascular insult [15]. The data by Izui et 
a! demonstrating that DNA, [both single-stranded (denatured) 
and double-stranded (native)], have a propensity to bind to 
collagen along the basement membrane zone (BMZ) of the 
glomeruli and skin also offers an alternative explanation to t he 
CIC theory of pathogenesis [16]. Based upon Izui et a l's data, 
it is conceivable that "in situ" immune complex format ion 
composed of DNA, anti-DNA antibodies and not CJC plays the 
major pathologic role in the genesis of the glomerulonephritis. 
It is theorized that following the binding of the DNA to the 
BMZ, the anti-DNA antibody then binds to the DNA, forming 
an "in situ" immune complex. The "in situ" complex activates 
the complement sequence producing the int1ammation that 
ultimately destroys the glomeruli. Indirect evidence to indicate 
that DNA does preferentially bind to the sk in and BMZ in 
vivo, is found in studies evaluating the relationship of a positive 
lupus band test (immunoglobulin and complement deposition 
along the skin BMZ of normal appearing skin) and anti-nDNA 
antibodies [17,18]. Studies from several laboratories indicate a 
statistically significant increased prevalence of a + LBT and 
anti-DNA but not Sm, nRNP, Ro, etc., antibodies. Other 
studies have presented direct evidence for the presence of DNA 
antigens in some positive LBTs [19]. 
Finally, several studies of vasculitic lesions in SLE have 
described 2 distinct types of histopathologic inflammatory in-
filtrates . The most common is a leukocytoclastic angiitis; the 
second type is characterized by a mononuclear perivascular 
infiltrate in which mononuclear cells invade the blood vessel 
wa lls [20] . Similar histopathologic infiltrates have been de-
scribed in vasculitic lesions occurring in Sjogren's syndrome 
(SS) [21 ,22]. The leukocytoclastic vasculopathy is thought to 
be the result of CIC; the pathophysiologic mechanism respon-
sible for the mononuclear vasculopathy, however, is unknown. 
These data as recounted above, constitute a growing body of 
evidence suggesting that at least several possible pathophysio-
logic mechanisms may be responsible for SLE vasculitic and 
glomerulonephritic lesions. 
ssDNA ANTIBODIES 
ssDNA antibodies are not specific for SLE. However, ssDNA 
antibodies may be the only positive serologic finding in some 
SLE patients failing to demonstrate a significant ANA titer 
[ 11] . Many of these patients possess significant photosensitive 
cutaneous disease. Recent studies indicate t hat approximately 
25 % of di scoid lupus patients possess ssDNA of the IgM isotype 
(Table III) [23]. These discoid lupus patients possessing ssDNA 
antibodies may be at risk to develop systemic features. In 
addition , acid elution studies of kidneys of SLE patients dying 
with glomerulonephritis, indicate an enhanced concentration 
of these ssDNA antibodies compared to the serum [24]. No 
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TABLE Ill. Features associated with ssDNA antibodies 
1. Associated with photosensit ive lupus dermatitis 
2. IgM ssDNA antibodies detected in 25 % of discoid lupus erythema-
tosus 
3. May be in volved in renal disease in lupus 
nD NA ant ibodies were detected. These studies have been in-
terpreted as indicating t hat ssDNA antibod ies, t heoretically in 
t he form of ssDNA, anti-ssD NA immune complexes, played a 
pathologic role in t he ge nesis of the glomerulonephrit is. 
These studies indicate t hat ssDNA ant ibody determinations 
may be an importa nt diagnostic and even prognostic test to be 
employed in t he eva luation of discoid lupus patients or in 
patients suspected of having lupus but who fail to demonstrate 
a significant ANA t iter. S ince ssDNA antibodies a re directed 
against purine and pyrimidine bases buried a nd sterically in-
accessible in t he double -stra nded DNA helix , it is possible to 
have high titer ssDNA ant ibodies and yet fail to demonstrate 
a positive ANA t iter [11] . 
TESTS FOR DNA 
DNA antibodies are generally detected by radioimmuno-
assay, immunoflu orescent techniques or ELISA assays. At t he 
present t ime, t he Crith.idea luciliae assay is a very popular assay 
for t he detection of nDNA ant ibodies (Fig 1). The kinetoplast 
of t his hemofl agell ate conta ins circular DNA and, t hus, t heo-
retically possesses t he same antigenic dete rminates as nDNA. 
However, recent experi ence with this assay by Gilliam's and 
other groups indicate that t he kinetoplast may conta in other 
antigenic determinants and t hus not be abso lu tely specific for 
nDNA as has been previously presumed [25,26]. The nature of 
t hese other antigenic determinants in t he Crithidea kinetoplast 
is/are unknown but some preliminary data suggest that t hey 
may be histones . 
It is important to note t hat t he vast majority of DNA -posit ive 
patien ts make quantities of an ti-DNA antibodies in t he llg 
range. Thus, very sensit ive tec hniques, i.e., radioimmunoassays, 
Crith.idea luciliae and ELISA technologies have been developed 
(27]. Only occasional SLE patients possess significant quan-
t it ies of ant i-nDNA antibodies to be detected in the less sen-
sitive gel double-diffusion assay. 
RNA ANTIBODIES 
The second major class of autoant ibodies in SLE are directed 
against RNA macromolecules. Lupus patients make autoant i-
bodies against a variety of RNA prote ins. Recent ly, it has been 
determined that systemic lupus patients commonly make auto-
antibodies reactive aga inst a newly described class of small 
molecular weight RNA proteins residing predominant ly in t he 
nucleus and to a lesser extent in t he cytoplasm of t he cell 
[4,5 ]. These RNA proteins conta in specific RNA nucleotides 
(Fig 2, Table IV). These mo lecules"are termed small nuclea r 
ribonuclear proteins (snRNPs) and small cytoplasmic ribonu-
clear proteins (scRNPs), respectively. It is estimated that t hese 
ribonuclear prote ins compose 0.1%-1% of t he total RNA con-
tent of cells. These small ribonuclear proteins are phyloge net-
ically highly conse rved. They a re capped (3-methyl guanosine 
at the 3 ' position) or uncapped and are synthesized by either 
RNA polymerase II or III (Table IV). The exact function of 
t hese small ribonuclea r proteins is/a re unknown but the evi-
dence at t he present t ime indicates t hat t hese ribonuclear 
proteins are probably involved in RNA process ing such as 
splicing and excision and posttranslatio na l activities. 
SM ANTIBODIES 
The first autoant ibody directed against t hese snRNPs to be 
described was t he S m ant ibody (named after an abbreviation 
of the surname of t he first patient in whom it was initially 
detected) [29]. This is an autoantibody directed against a 
FIG 1. Posit ive Crithidea luciliae assay. Crithidea organisms over-
layed with a nt i-nONA containing lupus serum and developed wi th a 
fluorescein labelled ant ihuman globulin preparation . Kinetoplast con-
ta ining circular DNA stains apple green . 
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FIG 2. Polyacrylamide gel electrophoresis of small RNAs from He Ia 
ce lls precipitated by autoant ibodies from system ic lupus erythematosus 
and other pat ients. Hela cells were labeled with 32P O, and tota l ce ll 
extracts prepared. (Reprinted by permission of the authors and the 
editor of the J ournal of Clinical investigation [28].) 
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TABLE TV. Antibodies against small ribonucleoproteins 
Antibody Class of RNA 
nucleoli des Other features 
Anti-nRNP U, Capped with trimethylgu-
anosine; synthesized by 
RNA polymerase II 
Anti-Sm U~, U2 , U4 , U5 , U 6 All but U6 capped with 
trimethylguanosine; UG 
capped by unknown nu-
cleotide; synthesized by 
RNA polymerase II 
Anti -Ro (SS-A) Y1-Yr," Noncapped; synthesized by 
RNA polymerase III 
Anti-La (SS-B) Many RNAs including Noncapped; synthesized by 
Y,-Y5, VA RNAsb RNA polymerase III 
and EBER RNA' 
"Cytoplasmic RNA nucleotide. 
"VA RNAs = Viral-associated RNAs of adenovirus. 
'EBER RNA= Epstein-Barr virus-associated RNAs. 
snRNP containing 2 polypeptides of approximately 15,000 and 
17,000 M, [30]. The U1, U2, U4, U5, and U6 series of RNA 
nucleotides ·(U connoting uridine-rich RNA) bind to this pro-
tein. (Fig 2, Table IV). These anti-Sm antibodies are highly 
specific for SLE. These antibodies almost never occur alone 
and are almost always found in the presence of anti-nRNP 
antibodies. There is some evidence to suggest that these anti-
bodies are found in a lupus patient population possessing an 
increased incidence of central nervous system and renal disease 
[31 ). 
nRNP ANTIBODIES 
Antibodies directed against nRNP are directed against a 
snRNP (approximately 85,000 daltons) containing the U1RNA 
nucleotide (Fig 2) [30]. The U1RNA protein complex is the 
most plentiful of the snRNPs ( -106 copies/cell). Recent evi-
dence employing anti-nRNP and anti-Sm antibodies as probes 
indicates that the UlRNA may play a significant role in the 
excision and splicing process in the formation of messanger 
RNA. These autoantibodies, both of which are directed against 
proteins containing the U1RNA, block this process [32) . 
The nRNP(U1 snRNP) antibodies are found predominantly 
in a patient population satisfying the American Rheumatism 
Association (ARA) criteria for the diagnosis of SLE (Table V) 
[33). However, there is a definite small group of patients 
possessing nRNP antibodies who have clinical features of scle-
roderma, lupus, and dermatomyositis. These patients have been 
termed the mixed connective tissue disease (MCTD) syndrome 
[36). The common clinical features of the MCTD syndrome are 
listed in Table VI. Some investigators ascribe to all nRNP 
positive patients, the designation of the MCTD. These nRNP 
patients, however, are not homogeneous in clinical presentation 
and clinically may change with the progression of time. For 
example, a long-term follow up of the original nRNP-po~itive 
MCTD patients has indicated that a majority of these patients 
have evolved into a clinical picture of scleroderma or SLE. I 
believe all would agree, however, that this group of nRNP-
positive patients have a significantly lower prevalence of clini-
cal renal disease than the nDNA-positive lupus patients and, 
thus, a better prognosis. 
LA ANTIBODIES 
Antibodies against the La antigen are directed against a 
snRNP containing a heterogeneous group of RNA nucleotides 
including RNA nucleotides of the yl- y5 (cytoplasmic) series as 
well as RNA nucleotides of adenovirus (VA-RNA) and the 
Epstein-Barr virus [5,36] (Table IV). Molecular weight studies 
of the La protein employing polyacrylamide gel electrophoresis 
(PGE) by several laboratories indicate an approximate 41,000 
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TABLE V. Clinical diagnoses in 43 nRNP-positive patients 
Diagnosis 
Mixed connective tissue disease 
Progressive systemic sclerosis 
Systemic lupus erythematosus 
Rheumatoid arthritis 
Drug-induced systemic lupus ery-
thematosus 
Nonrheumatic disease 
Number of 
patients 
5 
1 
34 
1 
1 
Percentage 
12 
2 
80 
2 
2 
2 
TABLE VI. Clinical features associated with nRNP autoantibodies 
1. Sclerodactyly 
2. Sclerodermatous features 
3. Raynaud's phenomenon 
4. Esophageal dysmotility 
5. Decreased prevalence of renal disease 
FIG 3. Immunoblotting analysis of partially purified human spleen 
Ro/La antigens and a representative panel of SSA/Ro and SSB/La 
sera (lanes 1-4) , SSA/Ro sera (lanes 5-8), SSB/La sera (lanes 9-12), 
and normal human sera (lanes 13-16). The SSA/Ro antisera reacted 
with a protein band of 58k M, (shown by arrow), the SSB/La antisera 
reacted with 2 close bands of 40k and 42k M, (shown by arrow) , 
respectively. Antisera with SSA/Ro and SSB/La specificities reacted 
with both groups of proteins. Normal human sera did not show reactiv-
ity. Molecular weight standards are listed on the left of lane I as follows: 
(a) phosphorilase (94k, (b) albumin (68k), (c) ovalbumin (45k) , and (d) 
soybean trypsin inhibitor (20k). 
dalton molecular weight (Fig 3) [37,*]. The La antibody (named 
after an abbreviation of the surname in whom this antibody 
was first detected), is immunologically identical to the SS-B 
and SjT antibody systems described in SS (38,39). This anti-
body system is almost always found together with the Ro(SS-
A) antibody system (see below). Anti-La antibodies are seen in 
approximately 10% of SLE patients. This antibody system is 
almost never seen in the normal patient population. 
RO ANTIBODIES 
The Ro antibody is directed against a 58-60 kD protein 
present in greatest concentration in the brain and heart and is 
identical to the SS-A antibody systems described in SS (Fig 3) 
[36,40,41). This antibody system is also probably identical to 
the SjD and Ha antibody systems [39). The Ro antibody system 
has proved most important in the evaluation of lupus patients 
possessing prominent photosensitive cutaneous lupus lesions. 
In addition to prominent photosensitive lupus lesions, these 
Ro-positive lupus patients frequently are rheumatoid-factor 
positive [11,13) and may have SS. Most important, these Ro-
positive patients have a low prevalence compared to nDNA 
positive lupus of renal disease (Table VII). Ro-positive lupus 
patients have been described under the heading of ANA-nega-
tive SLE [11], subacute cutaneous lupus erythematosus (SCLE) 
(7], homozygous C2 and C4 deficient associated with a lupus-
* Herrera-Esparza R, Halim HY, Provost TT, Diaz LA: A sensitive 
and specific assay to detect SSA/Ro and SSB/La antibodies. In press. 
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TABLE VII. Clinical and Laboratory features of Ro-positive SLE 
patients 
1. Photosensitive lupus dermatitis 
2. Sjogren's syndrome 
3. Rheumatoid factor 
4. Low prevalence of renal disease 
TABLE VIII. Ro(SS-A) antibody clinical associations 
1. ANA negative SLE approximate ly (70%) 
2. Subacute cutaneous lupus erythematosus (SCLE) (approximately 
70 %) 
3. c2 deficient lupus- like disease (75 %) 
4. C, deficient lupus-like disease (50%) 
5. Neonatal lupus erythematosus (approximately 100%) 
6. Aged lupus patients (approximately 90%) 
7. Japanese (? all Oriental) lupus patients (50%) 
8. Sjogren's syndrome patients (40%) 
(% ) Percent of patients with particular clinica l designation who are 
Ro(SS-A)-positive. 
like syndrome [42], and neonatal lupus [43,44] (Table VIII). 
These patients all have in common the presence of an intense 
photosensitive (many of these patients burn through window 
glass) cutaneous lupus dermatitis. In our experience with ap-
proximately 150 Ro-positive lupus patients, 40% of these pa-
tients have a distinctive, annular, polycyclic lupus dermatitis 
demonstrating sparse scaling and little , if any, scar formation. 
Because these lesions occur in a predominantly cutaneous lupus 
patient population, who at least 50% of the time satisfy pre-
dominantly the minor criteria for the diagnosis of SLE, these 
patients have been aptly termed by Sontheimer and Gilliam as 
having SCLE [7]. 
Most recent data indicate there is a striking increased prev-
alence of the Ro antibody in lupus patients with the onset of 
t heir disease process after the age of 55. Other recent studies 
indicate that the Ro antibody occurs much more frequently in 
Japanese (50%) than in Occidental (25%) lupus patients. The 
reason(s) for these statistically significant associations of the 
Ro antibody with elderly and Japanese (and perhaps all Ori-
ental lupus patients) is/are unknown . 
Perhaps most importantly, the Ro and La antibodies have 
been described to occur in almost all mothers and infants with 
t he neonatal lupus syndrome [45,46]. These studies have dem-
onstrated that the mother produces these antibodies and these 
antibodies pass across the placenta to the affected infant who 
may die in utero, be born with isolated congenital heart block 
(47], or in its most benign form, demonstrate a lupus dermatitis 
(most commonly, SCLE). The Ro antibody and lupus derma-
titis generally disappear by 6 months of age. The congenital 
heart block, however, is persistent. At present, the pathophys-
iologic mechanism(s) operative in th~ genesis of the skin and 
heart disease in the infant is/are unknown. These data, how-
ever, constitute the best evidence at the present time that the 
Ro and La antibodies are capable of inducing clinical features 
of lupus erythematosus. 
In addition to a prominent association with cutaneous lupus 
patients, the Ro antibody as detected by a very sensitive ELISA 
assay, has been found to occur in almost all SS patients. 
Approximately 40-45% of SS patients demonstrate the Ro 
antibody by gel double-diffusion (large quantities of Ro anti-
body). SS patients frequently demonstrate evidence of cuta-
neous vasculitis [22] . The 2 most common presentations of 
cutaneous vasculitis are palpable purpura of the lower extrem-
ities (this dermatitis is indistinguishable from Waldenstrom's 
hyperglobulinemia) and urticaria-like vasculitis. The vasculitis, 
associated with high titers of the Ro antibody (ELISA test 
positive; gel double-diffusion positive), is generally a leukocy-
toclastic angiitis and is frequently accompanied by rheumatoid 
factor activity. The vasculopathy occurring in low-titered Ro-
positive SS patients (ELISA test positive, gel double-diffusion 
negative) is generally characterized as a mononuclear vasculo-
pathy. The most important clinical observation associated with 
the cutaneous vasculitis in SS is that approximately 60% of 
these vasculitic SS patients also have evidence of central and 
peripheral nervous system disease. Evidence suggests that the 
central and peripheral nervous disease is also vasculitic in 
origin. 
RNA ANTIBODY TESTING 
Tests for antibodies against the RNA macromolecules are 
most commonly performed employing gel double-diffusion . In 
the past, hemagglutination techniques using RNAase had been 
employed to detect RNA-sensitive extractable nuclear antigen 
(ENA) antibodies. ELISA assays for all these RNA antibodies 
will probably be soon available. 
From a conceptual point of view, it is intriguing to observe 
that lupus patients make relatively large quantities of anti-
RNA antibodies (mgm) which can readily be detected in gel 
double-diffusion. Considering the previous bias on the part of 
the immunologic community regarding the importance of the 
anti-DNA antibodies in lupus, it is interesting to note that 
lupus patients make anti-RNA antibodies as frequently as they 
do anti-DNA antibodies and generally make much larger quan-
tities (Table I). 
HISTONE ANTIBODIES 
The last antibody system of importance in SLE is anti-
histone antibodies. Histones represent a phylogenetically, 
highly conserved class of basic proteins which readily bind to 
DNA and are involved in packing the DNA helix. There are 5 
classes of histones (H1, H2A/ H2B, H3, and H4). The H2A/ 
H2B H3 and H4 histones are wrapped by segments of approx-
imat~ly l46 base pairs of DNA (nucleosomes) . The H1 histone 
binds to DNA segments linking the individual nucleosomes. 
Approximately 30% of SLE patients possess antihistone 
antibodies [2]. However, greater than_ 90% of hydrala~i~e and 
procainamide drug-induced lupus patients possess ant!l11Stone 
antibodies. Interestingly, procainamide-induced lupus patients 
preferentially make antibodies against ~he H2A( H2B histones 
whereas hydralazine-induced lupus-hke patients demon-
strate a preference for the production of H3,_ H4 hist~ne anti-
bodies. The mechanism whereby these drugs mduce this lupus-
like state is unknown although there is some evidence to 
indicate these drugs may bind to DNA. In addition, hydrala-
zine-induced lupus patients appear to have a number of char-
acteristics [47). These are: (1) hydralazine dosage of greater 
than 300 mgm/ day; (2) slow acetylators (hepatic acetyltrans-
ferase); (3) predominance of females versus males (4:1); and, 
(4) a statistically significant increased prevalence of the HLA-
DR4 phenotype. 
HISTONE ANTIBODY TESTING 
Histone antibodies can be detected employing a multistep 
immunofluorescent procedure in which the test serum is first 
titered (2). The substrate is then washed with 0.1 HCl buffer 
which removes the histones; the test serum is then titered on 
this histone-free substrate; the histone-free substrate is then 
reconstituted with histones and the test serum titered again. 
In addition to the lupus-like syndromes induced by hydrala-
zine and procainamide, D-penicillamine has also been shown 
to induce a lupus-like disease process [ 48]. In marked contrast 
to the lupus-like disease induced by hydralazine and procain-
amide, the penicillamine-induced lupus patients develop lupus 
dermatitis nDNA antibodies and glomerulonephritis. 
HLA STUDIES 
HLA studies indicate that high binding titers of ssDNA and 
nDNA may be associated with a statistically significant in-
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TABLE IX. Relationship of Ro and La antibody responses to HLA-DR 
phenotypes 
HLA -OR Ro (+) Ro (-) p Value phenotype 
2 60% 37.8% .04 
3 52.5% 2.6% .0018 
La(+) La( - ) p Value 
2 35.7% 47 % NS 
3 71.4 % 27 % .0034 
creased prevalence of the HLA-DR2 phenotype. No HLA as-
sociation, however, was detected with either the presence of 
Sm or nRNP antibodies. 
The Ro antibody occurs in a statistically s ignificant associ-
ation with the HLA-DR2 and DR3 phenotypes [3,6,7]. In fact, 
one study indicates that the Ro antibody occurred 95% of the 
time with e ither the HLA DR2 or DR3 phenotypes. The La 
antibody, however, was found to occur in a statistically s ignif-
icant associat ion with the HLA-DR3 and not t he HLA-DR2 
phenotype (49, 50] (Table IX). 
HLA stu_dies of neonatal lupus infants and their mothers and 
normal babies of Ro-positive mothers have demonstrated t hat 
the neonatal lupus syndrome occurs on a maternal, genetic 
background of HLA-DR3, MB2, whereas, the maternal, genetic 
background of the Ro-positive mothers of normal children is 
HLA-DR2; MBl 147,48]. The infants don't demonstrate an 
increased express ion of a ny one phenotype. These studies 
strongly suggest a factor produced by the HLA-DR3 but not 
DR2 mothers is involved in the pathogenesis of t he neonatal 
lupus syndrome. These studies are a lso important because they 
demonstrate a striking associat ion of the express ion of Ro and 
to a lesser extent, the La antibodies with t he maternal HLA-
DR3 phenotype but the clinical manifestations of the lupus 
syndrome i.e., cutaneous lupus lesions and cardiac conduction 
in t he infant a re not HLA-linked. 
This brie f account of the current research occurring in auto-
antibodies in lupus indicates a broad degree of activity and the 
promise of new and exc iting findings. 
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